FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hurley Ariel		2. Date of Event Requiring Statement (Month/Day/Year) 03/06/2019		3. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ]					
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION				Relationship of Reporting Persi (Check all applicable)     Director  Officer (circle title)	10% Owne	er (Mo	If Amendment, Date of Original Filed (Month/Day/Year)      Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person		
45 SIDNEY STREET	X Officer (give title below)  Principal Accounting			Other (spe below) ng Officer	6. II				
(Street) CAMBRIDGE MA 02139							Form filed by More than One Reporting Person		
(City) (State)	(Zip)								
		Table I - Noi	n-Derivat	ive Securities Beneficial	ly Owned				
1. Title of Security (Instr. 4)				. Amount of Securities Beneficially Owned (Instr. 4)			Nature of Indirect Beneficial Ownership str. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Date Exercisable	Expiratior Date	Title	Amount or Number of Shares	Price of Direct (D) or Indirect Security (I) (Instr. 5)			
Stock Option (Right to	Buy)	(1)	10/08/2024	Common Stock	17,994	1.87	D		
Stock Option (Right to	Buy)	(2)	02/10/2025	Common Stock	5,454	8.8	D		
Stock Option (Right to	Buy)	(3)	02/03/2026	Common Stock	5,000	15.01	D		
Stock Option (Right to	Buy)	(4)	02/16/2027	Common Stock	9,000	36.05	D		
Stock Option (Right to	Buy)	(5)	02/16/2028	Common Stock	12,000	81.44	D		
Stock Option (Right to	Buy)	(6)	03/01/2029	Common Stock	11,399	86.6	D		
Restricted Stock Units		(7)	(7)	Common Stock	3,069	(8)	D		

### Explanation of Responses:

- 1. The Reporting Person was granted an option to purchase 20,909 shares of the Issuer's common stock on October 8, 2014. 2,915 shares underlying the option were previously exercised and sold by the Reporting Person. This option vested with respect to 25% of the shares underlying the option on September 15, 2015 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.
- 2. This option vested with respect to 1/48 th of the shares underlying the option on March 10, 2015 and as to an additional 1/48 th of the shares underlying the option each month thereafter.
- 3. This option vested with respect to 1/48th of the shares underlying the option on March 3, 2016 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- 4. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.

  5. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- 5. Inis option vested with respect to 1/48th of the shares underlying the option on March 19, 2018 and as to an additional 1/48th of the shares underlying the option each month therea.
- 6. This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- $7. \ The \ restricted \ stock \ units \ vest \ in \ four \ equal \ annual \ installments \ on \ March \ 1, \ 2020, \ 2021, \ 2022 \ and \ 2023.$
- 8. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

## Remarks:

Exhibit 24 - Limited Power of Attorney

/s/ Christopher Frankenfield, Attorney-in-Fact 03/15/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Tracey McCain, Christopher Frankenfield and Michael Landsittel, and each of themindividually, and with full power of substitution, the undersigned's true and lawful attorneyin-fact to:

- (1) Complete and execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or ten percent (10%) shareholder of Blueprint Medicines Corporation, a Delaware corporation (the "Company"), any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned's company or partnership, as the case may be, pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or the rules and regulations thereunder;
- (2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such instruments, certificates or documents required to be filed pursuant to Sections 13 and 16 of the Exchange Act or the rules or regulations thereunder and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 6, 2019.

By: /s/ Ariel Hurley

Name: Ariel Hurley